Genmab A (GMAB) Long-Term Deferred Tax (2018 - 2026)

Genmab A (GMAB) has reported Long-Term Deferred Tax for 9 consecutive years, with $173.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Deferred Tax rose 36.22% year-over-year to $173.0 million; the trailing twelve-month figure through Jun 2026 stood at $173.0 million (up 36.22% YoY), and the FY2025 full-year result was $171.0 million, up 34.65% from the prior year.
• Long-Term Deferred Tax steadied at $173.0 million in Q2 2026 per GMAB's latest filing, from $173.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $173.0 million in Q1 2026 and bottomed at $19.9 million in Q4 2023.
• Historically, Long-Term Deferred Tax has averaged $72.7 million across 5 years, with a median of $28.3 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax dropped 20.36% in 2022, then surged 531.31% in 2025.
• Over 5 years, Long-Term Deferred Tax stood at $22.7 million in 2022, then declined by 12.17% to $19.9 million in 2023, then jumped by 324.19% to $84.5 million in 2024, then surged by 102.41% to $171.0 million in 2025, then grew by 1.17% to $173.0 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $173.0 million, $173.0 million, and $171.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.